0001354488-14-005745.txt : 20141114 0001354488-14-005745.hdr.sgml : 20141114 20141114132915 ACCESSION NUMBER: 0001354488-14-005745 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141114 DATE AS OF CHANGE: 20141114 EFFECTIVENESS DATE: 20141114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Puramed Bioscience Inc. CENTRAL INDEX KEY: 0001409565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205510104 STATE OF INCORPORATION: NC FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52771 FILM NUMBER: 141222545 BUSINESS ADDRESS: STREET 1: PO BOX 677 STREET 2: 1326 SCHOFIELD AVENUE CITY: SCHOFIELD STATE: WI ZIP: 55476 BUSINESS PHONE: 715-359-6373 MAIL ADDRESS: STREET 1: PO BOX 677 STREET 2: 1326 SCHOFIELD AVENUE CITY: SCHOFIELD STATE: WI ZIP: 55476 NT 10-Q 1 pmbs_nt10q.htm NOTICE OF LATE FILING pmbs_nt10q.htm

 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
 
FORM 12b-25
 
NOTIFICATION OF LATE FILING
OMB APPROVAL
  
OMB Number: 3235-0058
  
Expires: August 31, 2015
  
Estimated average burden hours per response ... 2.50
  
   
SEC FILE NUMBER
  
000-52771
  
   
CUSIP NUMBER
  
   
 
(Check one):
  
 oForm 10-K  o  Form 20-F  o  Form 11-K  x  Form 10-Q  o  Form 10-D  o  Form N-SAR  o  Form N-CSR
     
   
For Period Ended:
September 30, 2014
     
   
o   Transition Report on Form 10-K
     
   
o  Transition Report on Form 20-F
     
   
o  Transition Report on Form 11-K
     
   
o  Transition Report on Form 10-Q
     
   
o  Transition Report on Form N-SAR
     
   
For the Transition Period Ended:
 
 
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
PART I - REGISTRANT INFORMATION
 
PURAMED BIOSCIENCE, INC.
Full Name of Registrant
 
 
Former Name if Applicable
 
P.O Box 677
1326 Schofield Avenue
Address of Principal Executive Office (Street and Number)
 
Schofield, WI 54476
City, State and Zip Code
 
 
 
 
 
 
PART II - RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
x
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 
x
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
 
o
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
PART III - NARRATIVE
 
Registrant was not able to obtain all information prior to filing date and the accountant could not complete the required financial statements and management could not complete Management’s Discussion and Analysis of such financial statements by November 14, 2014.
 
PART IV - OTHER INFORMATION
 
(1)
  
Name and telephone number of person to contact in regard to this notification
 
         
Russell W. Mitchell
  
(715)
  
359-6373
(Name)
  
(Area Code)
  
(Telephone Number)
 
(2)
  
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
   
Yes x    No o
     
(3)
  
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
   
Yes o     No x
     
   
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
     
 

 
2
 
 
PURAMED BIOSCIENCE, INC.
 (as Specified in Charter)
 
Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
           
           
Date:
  
November 14, 2014
By:
/s/ Russell W. Mitchell
  
       
Russell W. Mitchell
Chief Executive Officer
  

 
3